Nugget Effect Explained
Renforth Resources (C.RFR) put out a press release today on the results of metallic screen assays on core from its New Alger project at the Cadillac Break in Quebec.
Day: March 9, 2020
Renforth Completes Initial Metallic Screen Assays at New Alger 68% of Samples Display Nugget Effect, Give Higher Gold Values in Plus Fraction
- A total of 76 samples were selected and metallic screen assayed from the core rejects from Fall 2019 drill program
- Results from metallic screen selection demonstrate the presence of coarse gold
- 51 out of 76 samples submitted for metallic screen returned assay values from the “plus” portion of the metallic screen higher than the original fire assay values. This includes 70.1 g/t Au in the plus fraction where the original full sample fire assay was 11.2 g/t Au, the new full sample metallic screen assay is 10.5 g/t Au. The lower full sample values reflect the inclusion of screened, finer material of a lower grade as discussed below.
PICKERING, ON / ACCESSWIRE / March 9, 2020 / Renforth Resources Inc. (CSE:RFR) (OTC Pink:RFHRF) (WKN – A2H9TN) (“Renforth” or the “Company”) is pleased to confirm, via an initial metallic screen program, the presence of coarse, or “nugget effect” gold, which, in 51 of the 76 samples tested returned a higher “plus screen” assay value than the original full sample fire assay value, as seen below.
FSD Pharma Begins Phase 1 In-human Safety and Tolerability Study of Ultra Micro-Palmitolylethanolamide (PEA)
FSD Pharma Inc. (Nasdaq: HUGE) (CSE: HUGE) (FRA: 0K9A) (“FSD Pharma” or the “Company”) today announced receipt of approval from the Ethics Committee of the Alfred Hospital, part of the Alfred Health group of hospitals serving the state of Victoria in Australia, to initiate a Phase 1, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability and pharmacokinetics of single and multiple ascending doses of ultra-micronized-PEA in normal healthy volunteers.